Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Solitary Fibrous Tumor Arising in Thyroid Follicular Nodular Disease: A Case Report.

Pathobiology : journal of immunopathology, molecular and cellular biology·2026
Same author

Radiological Predictors of Visceral Pleural Invasion in Lung Cancers With Ground-Glass Opacity and Pleural Contact.

Clinical lung cancer·2026
Same author

Genetic Landscape of Oral Carcinoma Cuniculatum and its Histological Mimics.

Head and neck pathology·2026
Same author

Neurofibromatosis type 1-associated gastric gastrointestinal stromal tumor with PRC2 loss.

Clinical journal of gastroenterology·2026
Same author

Plexiform Fibromyxoma with MALAT1-GLI1 Fusion with Limited Myxoid Stroma, Aberrant KIT Expression, and Diffuse D2-40 Expression: A Case Report.

Diagnostics (Basel, Switzerland)·2026
Same author

Gastric-Type Adenomas of the Nonampullary Duodenum: Reappraisal of Clinicopathological and Molecular Features and a Proposal for Novel Classification.

The American journal of surgical pathology·2026

Related Experiment Video

Updated: Mar 1, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.5K

Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma.

Takeaki Ishii1, Kenichi Kohashi1, Hiroshi Ootsuka1

  • 1Department of Anatomic Pathology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.

Pathology, Research and Practice
|May 30, 2017
PubMed
Summary

Distinguishing retroperitoneal leiomyosarcoma (LMS) from dedifferentiated liposarcoma (DDLS) is crucial. MDM2 and myogenic markers aid diagnosis, but MDM2 analysis is recommended for accurate retroperitoneal sarcoma assessment.

Keywords:
ImmunohitochemistryLeiomyosarcomaLiposarcomaMolecular targeting therapyPathology

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.4K

Related Experiment Videos

Last Updated: Mar 1, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.5K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.4K

Area of Science:

  • Oncology
  • Pathology
  • Surgical Oncology

Background:

  • Accurate differentiation between retroperitoneal leiomyosarcoma (LMS) and dedifferentiated liposarcoma (DDLS) is clinically significant.
  • The dedifferentiated component of DDLS can exhibit leiomyosarcoma-like morphology, complicating diagnosis.
  • Immunohistochemical markers, including MDM2 and myogenic markers, are valuable but require further study in these specific retroperitoneal tumors.

Purpose of the Study:

  • To compare clinicopathological data of retroperitoneal LMS and DDLS.
  • To investigate the immunoreactivity of MDM2 and myogenic markers in these tumor types.
  • To evaluate the diagnostic utility and prognostic implications of these markers in distinguishing retroperitoneal LMS from DDLS.

Main Methods:

  • Retrospective analysis of clinicopathological data from 20 retroperitoneal LMS and 36 retroperitoneal DDLS cases.
  • Immunohistochemical assessment for MDM2 and myogenic markers.
  • Statistical analysis to compare patient demographics, marker expression, and prognosis.

Main Results:

  • Four (20%) of initially diagnosed LMS cases showed MDM2 immunoreactivity.
  • Fifteen (41.7%) of DDLS cases expressed two or more myogenic markers.
  • LMS with MDM2 overexpression was associated with older patient age and a worse prognosis compared to DDLS (P=0.0408).
  • No significant prognostic difference was observed between LMS without MDM2 overexpression and DDLS with myogenic differentiation.

Conclusions:

  • Systemic MDM2 expression analysis is recommended for all retroperitoneal sarcoma cases.
  • Over-reliance on myogenic marker expression may lead to misdiagnosis when differentiating LMS from DDLS.
  • MDM2 and myogenic markers offer complementary information for accurate retroperitoneal sarcoma classification.